Press Releases

The European Chamber of Commerce of the Philippines (ECCP) welcomes the Food and Drug Administration’s recommendation to temporarily suspend the implementation of Administrative Order No. 2024-0016, which introduced significantly higher fees for medical device registration and licensing.

This is a prudent and compassionate decision, one that recognizes the serious concerns raised by stakeholders and prioritizes both regulatory strengthening and the need to safeguard healthcare accessibility for all Filipinos.

We commend the FDA for taking this step and initiating a constructive pause to allow for further dialogue, review, and recalibration of the policy. The ECCP has been actively engaged in raising these concerns and proposing balanced, practical solutions that support modernization while protecting patients, small and medium enterprises, and the broader health system.

We are grateful that our collective voice was heard, and we reaffirm our commitment to work hand-in-hand with the government and industry partners to co-create policies that are fair, inclusive, and aligned with our shared goal of delivering quality, affordable healthcare to every Filipino.

Let this development mark not just a policy pause, but a renewed opportunity for genuine collaboration.